CEFTARVA ® T (Ceftriaxone Sodium & Tazobactam Sodium 1.125g) , CEPHALOSPORIN ANTIBIOTIC
CEFTARVA® T is supplied as sterile powder in glass vial.
CEFTARVA® T IV Injection: Combipack containing sterile Ceftriaxone Sodium USP
equivalent to Ceftriaxone Anhydrous 1000mg tazobactam Sodium equivalent
to Tazobactam USP 125mg and 10 ml Water for Injection IP for IV injection.
CEFTARVA® T is a sterile, semisynthetic, broad spectrum cephalosporin antibiotic. Tazobactam sodium is a penicillinic acid sulfone Beta-lactamase inhibitor with a structure similar to that of sulbactam & clavulanic acid. It inactivates
susceptible Beta-lactmase by irreversibly binding to the catalytic region of the enzyme. The combination of
Tazobactam and ceftriaxone sodium CEFTARVA® T is active against all the organisms resistant to Ceftriaxone.
FORMULATIONS AVAILABLE: INJECTION
COMPOSITION
Each vial contains sterile Ceftriaxone Sodium IP equivalent to Ceftriaxone Anhydrous 1000mg tazobactam Sodium equivalent to Tazobactam USP 125mg
and 10 ml Water for Injection IP for IV injection.
DOSAGE FORM
Powder for reconstitution (intravenous (I.V)/intramuscular (I.M).
PHARMACOKINECTICS
Ceftriaxone interferes with the biosynthesis of the peptidoglycan component of the bacterial cell way by binding to and inactivating penicllin-binding proteins
(PBPs). Tazobactam is a penicillanic acid sulfone derivative with β-lactamase inhibitory properties. It enhances the activity of β-lactam antibacterials
against β-lactamase-producing bacteria.
Distribution
Ceftriaxone: 98% bound to plasma proteins; crosses the blood brain barrier. Tazobactam: About 30% bound to plasma proteins; widely distributed to
tissues and body fluids.
Excretion
Ceftriaxone: Elimination half-life is about 8.7 hours; 33-67% removed as unchanged drug. Tazobactam: Removed mainly via kidneys with 80% of an administered dose as unchanged drug.
INDICATIONS
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CEFTARVA® T Injection, it should be used only to treat or prevent infections that are proven or strongly
suspected to be caused by susceptible bacteria.
CEFTARVA® T Injection is mainly indicated in the following conditions:
Lower respiratory tract infections and community-acquired pneumonia, Acute bacterial otitis media, Skin and skin structure infections, Urinary tract infections, Uncomplicated gonorrhea,
Pelvic inflammatory disease, Bacterial septicemia, Bone and joint infections, Intra-abdominal infections, Bacterial meningitis, Pre-operative prophylaxis of infections associated with surgery.
CEFTARVA® T (Ceftriaxone Sodium & Tazobactam Sodium 1.125g) : 1000/125 mg once daily or in equally divided doses twice a day.
Pregnancy Related Information
Use with caution
Breast Feeding Related Information
Use with caution
Indications for Ceftriaxone + Tazobactam
It is a combination of third generation Cephalosporins Ceftriaxone and Beta-lactamase inhibitor Tazobactam. It enhances the activity of beta lactam antibacterials against beta lactamase producing bacteria.
1.Pneumonia
2.Lower respiratory tract infection
Typical Dosage for Ceftriaxone + Tazobactam
Adult:1000 mg of Ceftriaxone + 125 mg mg of Tazobactam / 500 mg of Ceftriaxone + 62.5 mg of Tazobactam / 250 mg of Ceftriaxone + 31.25 mg of Tazobactam to be given once a day depending upon the severity of the infection. Maximum daily dose: 4 g
Children: 50-75 mg / kg every 12 hours. Maximum daily dose: 2g.
Ceftriaxone
About Ceftriaxone
Third Generation Cephalosporin antibiotic(Parenteral).
Mechanism of Action of Ceftriaxone
Ceftriaxone is a 3rd generation cephalosporin which exerts its bactericidal action against both gram positive & gram negative organisms by inhibiting bacterial cell wall synthesis. Ceftriaxone inhibits transpeptidase & thus prevents cross linking of bacterial cell wall. Transpeptidase & associated proteins constitute various types of specific binding proteins which have affinity for cephalosporins like Ceftriaxone.
Pharmacokinets of Ceftriaxone
Absorption: Orally not well absorbed & should be given parenterally, Distribution: widely distributed & good CSF penetration, Metabolism: A portion of the drug is metabolized in the body. Excretion:
Excreted through urine & bile. A small portion of drug appears in breast milk.
Onset of Action for Ceftriaxone
Sudden
Duration of Action for Ceftriaxone
8 hours
Side Effects of Ceftriaxone
1.Nausea
2.Vomiting
3.Diarrhoea
4.Superinfection
5.Skin rash
6.Urticaria
7.Pseudomembranous colitis
8.Pain at site of injection
Contra-indications of Ceftriaxone
Hypersensitivity to Ceftriaxone
Special Precautions while taking Ceftriaxone
1.Hepatic impairment
2.Renal impairment
Pregnancy Related Information
Use with caution
Old Age Related Information
May be used
Breast Feeding Related Information
Use with caution
Children Related Information
May be used
Neonates: Use with caution
Indications for Ceftriaxone
1.Meningitis
2.Septicaemia
3.Typhoid
4.UTI
5.Prophylaxis in surgical infections
6.Lower respiratory tract infections
7.Pneumonia
8.Pelvic inflammatory disease
9.STD
10.Bacteraemia
Interactions for Ceftriaxone
Alcohol: Disulfiram like reaction.
Aminoglycosides & fruesmide: Nephrotoxicity potentiated.
Chloramphenicol: Decreased efficacy of ceftriaxone.
Typical Dosage for Ceftriaxone
Adults: 1g to 2gm I.M. or I.V. Once daily or two times daily
Maximum adult dose: Up to 4gm/day
Meningitis & Endocarditis: 1 to 2gm I.M. or I.V twice daily; two weeks for meningitis & four weeks for endocarditis
Gonorrhea: 250mg once daily
Children: 50 to 100 mg/kg/day I.M or I.V. two times daily
Maximum child dose: 2g/day
Meningitis & Endocarditis: 50 to 100 mg/kg/day twice daily; two weeks for meningitis & four weeks for endocarditis
Schedule:
H
Effects of Missed Dosage Ceftriaxone
Take the missed dose as soon as noticed and if it is the time for next dose then skip the missed dose. Continue the regular schedule. Do not double the dose.
Effects of Overdose Ceftriaxone
Symptoms of over dosage include neuromuscular disorders & some times seizure may get precipitated. Treatment is supportive.
Tazobactam
About Tazobactam
A Penicillanic acid sulfone beta-lactamase inhibitor, penams, To increase the antibacterial activity of penicillins against ?-lactamase?producing organisms.
Mechanism of Action of Tazobactam
Tazobactam is a Penicillanic acid sulfone beta lactamase inhibitor.Sulbactam has no significant antimicrobial activity, despite sharing the ?-lactam ring that is characteristic of beta-lactam antibiotics. This similarity in chemical structure helps the Tazobactam to act as a competitive inhibitor of beta-lactamase enzyme secreted by certain bacteria that are resistant to beta-lactam antibiotics. This inhibition restores the antibacterial activity of beta-lactam antibiotics against ?-lactamase-secreting resistant bacteria.It is usually given in combination with Piperacillin.
Side Effects of Tazobactam
1.Gastrointestinal disturbances
2.Headache
3.Dizziness
4.Insomnia
5.Rash
6.Pain
7.Hypertension
8.Edema
9.Pruritus
10.Agitation
11.Local reactions
Contra-indications of Tazobactam
Hypersensitivity to Tazobactam
Special Precautions while taking Tazobactam
1.Renal impairment
2.Cystic fibrosis
3.Haematopoiesis
4.Monitor electrolytes
5.Discontinue if bleeding disorders occur
Pregnancy Related Information
Use with caution
Old Age Related Information
Use with caution
Breast Feeding Related Information
Use with caution
Children Related Information
Contraindicated
Indications for Tazobactam
1.Skin infections
2.Pneumonia
3.Postpartum endometritis
4.Pelvic inflammatory disease
5.Appendicitis
6.Peritonitis
Typical Dosage for Tazobactam
IV Infusion over 30 minutes.
Adults: 3 to 4 grams of Piperacillin, in combination with 0.375 to 0.5 grams of Tazobactam, every 6 - 8 hours for 7 - 10 days.
Directions for Use
I.V. injection should be administered over at least 2–4 minutes.
I.V. infusion should be over a period of 30 minutes.
After reconstitution the solution should be administered by deep
I.M. injection. Doses greater than 1g should be divided and injected
at more than one site.
Reconstitute ceftriaxone/tazobactam with the appropriate diluent,
e.g., Water for Injection IP,Normal Saline Water, or Dextrose
Solutions.
Strength Amount of diluent for IM Amount of diluent for IV
(ml) (ml)
1g 3.6 9.6
Use reconstituted solution in the vial immediately.
INCOMPATIBILITY
Vancomycin, aminoglycosides, and fluconazole are physically
incompatible with ceftriaxone/tazobactam in admixtures. When any
of these drugs are to be administered concomitantly by intermittent
intravenous infusion, it is recommended that they be given
sequentially, with thorough flushing of the intravenous lines (with
one of the compatible fluids) between the administrations.
Do not use diluents containing calcium, such as Ringer’s solution or
Hartmann’s solution, to reconstitute SUPRAWAR vials or to further
dilute a reconstituted vial for IV administration. Particulate formation
can result.
NOTE: Parenteral drug products should be inspected visually for
particulate matter before administration.
STORAGE AND HANDLING INSTRUCTIONS
Store in a cool, dry place. Protect from light.
Keep out of reach of children.
Discard if reconstituted solution contains visible particulate matter.
DISCARD UNUSED PORTION.
How supplied
Vial with diluent in a carton
For further details, please contact:
Medical Advisor
Taj Pharmaceuticals Limited
Plot No.23-28, Hosur Road, Electronics City,
Bangalore - 560 100. India
Manufactured by:
Taj Pharma India Pvt. Ltd.
Plot No.14, EPIP, Phase-1, Jharmajri,
Baddi, Dist. Solan, HP - 173205
Marketed by:
Taj Pharma UK Limited
212 Great West Road
Brentford,Middlesex
TW8 9GS
TM - Trade Mark of Taj Pharmaceuticals Limited
“Mfd. under the technical guidance of TAJ GROUP, MUMBAI”
www.tajpharma.com
CEFTARVA® T is supplied as sterile powder in glass vial.
CEFTARVA® T IV Injection: Combipack containing sterile Ceftriaxone Sodium USP
equivalent to Ceftriaxone Anhydrous 1000mg tazobactam Sodium equivalent
to Tazobactam USP 125mg and 10 ml Water for Injection IP for IV injection.
CEFTARVA® T is a sterile, semisynthetic, broad spectrum cephalosporin antibiotic. Tazobactam sodium is a penicillinic acid sulfone Beta-lactamase inhibitor with a structure similar to that of sulbactam & clavulanic acid. It inactivates
susceptible Beta-lactmase by irreversibly binding to the catalytic region of the enzyme. The combination of
Tazobactam and ceftriaxone sodium CEFTARVA® T is active against all the organisms resistant to Ceftriaxone.
FORMULATIONS AVAILABLE: INJECTION
COMPOSITION
Each vial contains sterile Ceftriaxone Sodium IP equivalent to Ceftriaxone Anhydrous 1000mg tazobactam Sodium equivalent to Tazobactam USP 125mg
and 10 ml Water for Injection IP for IV injection.
DOSAGE FORM
Powder for reconstitution (intravenous (I.V)/intramuscular (I.M).
PHARMACOKINECTICS
Ceftriaxone interferes with the biosynthesis of the peptidoglycan component of the bacterial cell way by binding to and inactivating penicllin-binding proteins
(PBPs). Tazobactam is a penicillanic acid sulfone derivative with β-lactamase inhibitory properties. It enhances the activity of β-lactam antibacterials
against β-lactamase-producing bacteria.
Distribution
Ceftriaxone: 98% bound to plasma proteins; crosses the blood brain barrier. Tazobactam: About 30% bound to plasma proteins; widely distributed to
tissues and body fluids.
Excretion
Ceftriaxone: Elimination half-life is about 8.7 hours; 33-67% removed as unchanged drug. Tazobactam: Removed mainly via kidneys with 80% of an administered dose as unchanged drug.
INDICATIONS
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CEFTARVA® T Injection, it should be used only to treat or prevent infections that are proven or strongly
suspected to be caused by susceptible bacteria.
CEFTARVA® T Injection is mainly indicated in the following conditions:
Lower respiratory tract infections and community-acquired pneumonia, Acute bacterial otitis media, Skin and skin structure infections, Urinary tract infections, Uncomplicated gonorrhea,
Pelvic inflammatory disease, Bacterial septicemia, Bone and joint infections, Intra-abdominal infections, Bacterial meningitis, Pre-operative prophylaxis of infections associated with surgery.
CEFTARVA® T (Ceftriaxone Sodium & Tazobactam Sodium 1.125g) : 1000/125 mg once daily or in equally divided doses twice a day.
Pregnancy Related Information
Use with caution
Breast Feeding Related Information
Use with caution
Indications for Ceftriaxone + Tazobactam
It is a combination of third generation Cephalosporins Ceftriaxone and Beta-lactamase inhibitor Tazobactam. It enhances the activity of beta lactam antibacterials against beta lactamase producing bacteria.
1.Pneumonia
2.Lower respiratory tract infection
Typical Dosage for Ceftriaxone + Tazobactam
Adult:1000 mg of Ceftriaxone + 125 mg mg of Tazobactam / 500 mg of Ceftriaxone + 62.5 mg of Tazobactam / 250 mg of Ceftriaxone + 31.25 mg of Tazobactam to be given once a day depending upon the severity of the infection. Maximum daily dose: 4 g
Children: 50-75 mg / kg every 12 hours. Maximum daily dose: 2g.
Ceftriaxone
About Ceftriaxone
Third Generation Cephalosporin antibiotic(Parenteral).
Mechanism of Action of Ceftriaxone
Ceftriaxone is a 3rd generation cephalosporin which exerts its bactericidal action against both gram positive & gram negative organisms by inhibiting bacterial cell wall synthesis. Ceftriaxone inhibits transpeptidase & thus prevents cross linking of bacterial cell wall. Transpeptidase & associated proteins constitute various types of specific binding proteins which have affinity for cephalosporins like Ceftriaxone.
Pharmacokinets of Ceftriaxone
Absorption: Orally not well absorbed & should be given parenterally, Distribution: widely distributed & good CSF penetration, Metabolism: A portion of the drug is metabolized in the body. Excretion:
Excreted through urine & bile. A small portion of drug appears in breast milk.
Onset of Action for Ceftriaxone
Sudden
Duration of Action for Ceftriaxone
8 hours
Side Effects of Ceftriaxone
1.Nausea
2.Vomiting
3.Diarrhoea
4.Superinfection
5.Skin rash
6.Urticaria
7.Pseudomembranous colitis
8.Pain at site of injection
Contra-indications of Ceftriaxone
Hypersensitivity to Ceftriaxone
Special Precautions while taking Ceftriaxone
1.Hepatic impairment
2.Renal impairment
Pregnancy Related Information
Use with caution
Old Age Related Information
May be used
Breast Feeding Related Information
Use with caution
Children Related Information
May be used
Neonates: Use with caution
Indications for Ceftriaxone
1.Meningitis
2.Septicaemia
3.Typhoid
4.UTI
5.Prophylaxis in surgical infections
6.Lower respiratory tract infections
7.Pneumonia
8.Pelvic inflammatory disease
9.STD
10.Bacteraemia
Interactions for Ceftriaxone
Alcohol: Disulfiram like reaction.
Aminoglycosides & fruesmide: Nephrotoxicity potentiated.
Chloramphenicol: Decreased efficacy of ceftriaxone.
Typical Dosage for Ceftriaxone
Adults: 1g to 2gm I.M. or I.V. Once daily or two times daily
Maximum adult dose: Up to 4gm/day
Meningitis & Endocarditis: 1 to 2gm I.M. or I.V twice daily; two weeks for meningitis & four weeks for endocarditis
Gonorrhea: 250mg once daily
Children: 50 to 100 mg/kg/day I.M or I.V. two times daily
Maximum child dose: 2g/day
Meningitis & Endocarditis: 50 to 100 mg/kg/day twice daily; two weeks for meningitis & four weeks for endocarditis
Schedule:
H
Effects of Missed Dosage Ceftriaxone
Take the missed dose as soon as noticed and if it is the time for next dose then skip the missed dose. Continue the regular schedule. Do not double the dose.
Effects of Overdose Ceftriaxone
Symptoms of over dosage include neuromuscular disorders & some times seizure may get precipitated. Treatment is supportive.
Tazobactam
About Tazobactam
A Penicillanic acid sulfone beta-lactamase inhibitor, penams, To increase the antibacterial activity of penicillins against ?-lactamase?producing organisms.
Mechanism of Action of Tazobactam
Tazobactam is a Penicillanic acid sulfone beta lactamase inhibitor.Sulbactam has no significant antimicrobial activity, despite sharing the ?-lactam ring that is characteristic of beta-lactam antibiotics. This similarity in chemical structure helps the Tazobactam to act as a competitive inhibitor of beta-lactamase enzyme secreted by certain bacteria that are resistant to beta-lactam antibiotics. This inhibition restores the antibacterial activity of beta-lactam antibiotics against ?-lactamase-secreting resistant bacteria.It is usually given in combination with Piperacillin.
Side Effects of Tazobactam
1.Gastrointestinal disturbances
2.Headache
3.Dizziness
4.Insomnia
5.Rash
6.Pain
7.Hypertension
8.Edema
9.Pruritus
10.Agitation
11.Local reactions
Contra-indications of Tazobactam
Hypersensitivity to Tazobactam
Special Precautions while taking Tazobactam
1.Renal impairment
2.Cystic fibrosis
3.Haematopoiesis
4.Monitor electrolytes
5.Discontinue if bleeding disorders occur
Pregnancy Related Information
Use with caution
Old Age Related Information
Use with caution
Breast Feeding Related Information
Use with caution
Children Related Information
Contraindicated
Indications for Tazobactam
1.Skin infections
2.Pneumonia
3.Postpartum endometritis
4.Pelvic inflammatory disease
5.Appendicitis
6.Peritonitis
Typical Dosage for Tazobactam
IV Infusion over 30 minutes.
Adults: 3 to 4 grams of Piperacillin, in combination with 0.375 to 0.5 grams of Tazobactam, every 6 - 8 hours for 7 - 10 days.
Directions for Use
I.V. injection should be administered over at least 2–4 minutes.
I.V. infusion should be over a period of 30 minutes.
After reconstitution the solution should be administered by deep
I.M. injection. Doses greater than 1g should be divided and injected
at more than one site.
Reconstitute ceftriaxone/tazobactam with the appropriate diluent,
e.g., Water for Injection IP,Normal Saline Water, or Dextrose
Solutions.
Strength Amount of diluent for IM Amount of diluent for IV
(ml) (ml)
1g 3.6 9.6
Use reconstituted solution in the vial immediately.
INCOMPATIBILITY
Vancomycin, aminoglycosides, and fluconazole are physically
incompatible with ceftriaxone/tazobactam in admixtures. When any
of these drugs are to be administered concomitantly by intermittent
intravenous infusion, it is recommended that they be given
sequentially, with thorough flushing of the intravenous lines (with
one of the compatible fluids) between the administrations.
Do not use diluents containing calcium, such as Ringer’s solution or
Hartmann’s solution, to reconstitute SUPRAWAR vials or to further
dilute a reconstituted vial for IV administration. Particulate formation
can result.
NOTE: Parenteral drug products should be inspected visually for
particulate matter before administration.
STORAGE AND HANDLING INSTRUCTIONS
Store in a cool, dry place. Protect from light.
Keep out of reach of children.
Discard if reconstituted solution contains visible particulate matter.
DISCARD UNUSED PORTION.
How supplied
Vial with diluent in a carton
For further details, please contact:
Medical Advisor
Taj Pharmaceuticals Limited
Plot No.23-28, Hosur Road, Electronics City,
Bangalore - 560 100. India
Manufactured by:
Taj Pharma India Pvt. Ltd.
Plot No.14, EPIP, Phase-1, Jharmajri,
Baddi, Dist. Solan, HP - 173205
Marketed by:
Taj Pharma UK Limited
212 Great West Road
Brentford,Middlesex
TW8 9GS
TM - Trade Mark of Taj Pharmaceuticals Limited
“Mfd. under the technical guidance of TAJ GROUP, MUMBAI”
www.tajpharma.com
No comments:
Post a Comment